首页 > 最新文献

Clinical Microbiology and Infection最新文献

英文 中文
Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates: author's response.
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-21 DOI: 10.1016/j.cmi.2024.12.012
Christophe Le Terrier, Patrice Nordmann, Laurent Poirel
{"title":"Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates: author's response.","authors":"Christophe Le Terrier, Patrice Nordmann, Laurent Poirel","doi":"10.1016/j.cmi.2024.12.012","DOIUrl":"10.1016/j.cmi.2024.12.012","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sepsis: a summary of the SEP-1 quality measure and future considerations.
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-21 DOI: 10.1016/j.cmi.2024.12.019
Sias J Scherger, Andre C Kalil
{"title":"Sepsis: a summary of the SEP-1 quality measure and future considerations.","authors":"Sias J Scherger, Andre C Kalil","doi":"10.1016/j.cmi.2024.12.019","DOIUrl":"10.1016/j.cmi.2024.12.019","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia by Dinh et al.
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-21 DOI: 10.1016/j.cmi.2024.12.022
Tom A Yates, Fergus Hamilton
{"title":"Re: Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia by Dinh et al.","authors":"Tom A Yates, Fergus Hamilton","doi":"10.1016/j.cmi.2024.12.022","DOIUrl":"10.1016/j.cmi.2024.12.022","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: 'Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward' by tängdén et al.
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-18 DOI: 10.1016/j.cmi.2024.12.011
Balaji Veeraraghavan, Kamini Walia, Adrian Egli
{"title":"Re: 'Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward' by tängdén et al.","authors":"Balaji Veeraraghavan, Kamini Walia, Adrian Egli","doi":"10.1016/j.cmi.2024.12.011","DOIUrl":"10.1016/j.cmi.2024.12.011","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome? 优化疱疹病毒科脑炎的抗病毒剂量:改善预后的可行方法?
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-13 DOI: 10.1016/j.cmi.2024.12.008
Roland Nau, Jana Seele, Jacob Bodilsen, Uwe Groß

Background: Despite established antiviral therapy for herpes simplex virus, varicella zoster and cytomegalovirus encephalitis, the outcome remains poor.

Objectives: To assess pharmacokinetic (PK) and pharmacodynamic (PD) data of antiviral drugs in the central nervous system (CNS) to optimize the treatment of Herpesviridae encephalitis.

Sources: PUBMED search 1950 to September 2024, terms (1) "encephalitis" and ("HSV" or "VZV" or "CMV") or (2) cerebrospinal and ("(val)acyclovir" or "(val)ganciclovir" or "foscarnet" or "cidofovir").

Content: Antivirals against herpes viruses apparently act in a time-dependent manner. To suppress viral replication, drug concentration in the extracellular space at the site of the infection should be kept above the concentrations active in cell cultures for 24 h/d. Most data reflect delayed drug entry into lumbar cerebrospinal fluid (CSF). Ratios of the areas of the concentration/time curves (AUC) in CSF and serum (AUCCSF/AUCS) of acyclovir, ganciclovir and foscarnet are 0.15-0.3 in the absence of meningeal inflammation and increase in severe meningoencephalitis. Elimination half-lives (t1/2β) are longer in CSF than in plasma. CSF concentrations are rough approximations of drug concentrations in the cerebral extracellular fluid. Lumbar CSF concentrations are usually higher than ventricular or cisternal CSF concentrations tending to overestimate cerebral extracellular fluid concentrations. Provided the availability of adequate measurements in individual CNS compartments, antiviral concentrations and efficacy may be predicted by future PK/PD modelling. Probenecid holds the potential to reduce the efflux of antiviral drugs from the CNS.

Implications: The long t1/2β of antiviral drugs in CSF suggest relatively uniform steady state CSF levels at dosing intervals ≤12h and accumulation after repeated dosing. Probenecid is of unproven utility. To rapidly attain effective concentrations in the infected tissue, physiologically based pharmacokinetic and PK/PD modelling may be helpful. Until reliable PK/PD data are available, doubling the first dose should be considered.

背景:尽管对单纯疱疹病毒(HSV)、水痘带状疱疹病毒(VZV)和巨细胞病毒(CMV)脑炎采用了成熟的抗病毒疗法,但疗效仍然不佳:评估抗病毒药物在中枢神经系统(CNS)中的药动学(PK)和动力学(PD)数据,以优化疱疹病毒科脑炎的治疗:1. "脑炎 "和("HSV "或 "VZV "或 "CMV")或 2. 脑脊液和["(val)acyclovir "或"(val)ganciclovir "或 "foscarnet "或 "cidofovir"].内容:抗病毒药物对疱疹病毒的作用显然与时间有关。要抑制病毒复制,感染部位细胞外空间的药物浓度应保持高于细胞培养物中的活性浓度,每天持续 24 小时。大多数数据反映了药物进入腰部脑脊液(CSF)的延迟。阿昔洛韦、更昔洛韦和福斯奈德在 CSF 和血清中的浓度/时间曲线面积(AUC)之比(AUCCSF/AUCS)在无脑膜炎症时为 0.15-0.3,在严重脑膜脑炎时会升高。脑脊液中的消除半衰期(t1/2β)比血浆中长。脑脊液浓度是脑细胞外液(ECF)中药物浓度的粗略近似值。腰部 CSF 的浓度通常高于脑室或椎体内 CSF 的浓度,因此容易高估脑细胞外液(ECF)中的药物浓度。如果中枢神经系统各分区有足够的测量值,未来的 PK/PD 模型就可以预测抗病毒药物的浓度和疗效。丙磺舒具有减少中枢神经系统抗病毒药物外流的潜力:抗病毒药物在脑脊液中的t1/2β较长,这表明在用药间隔≤12小时时,脑脊液的稳态水平相对一致,重复用药后会出现蓄积。丙磺舒的作用尚未得到证实。为了快速达到感染组织中的有效浓度,基于生理的药代动力学(PBPK)和 PK/PD 模型可能会有所帮助。在获得可靠的 PK/PD 数据之前,应考虑将首次剂量加倍。
{"title":"Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?","authors":"Roland Nau, Jana Seele, Jacob Bodilsen, Uwe Groß","doi":"10.1016/j.cmi.2024.12.008","DOIUrl":"10.1016/j.cmi.2024.12.008","url":null,"abstract":"<p><strong>Background: </strong>Despite established antiviral therapy for herpes simplex virus, varicella zoster and cytomegalovirus encephalitis, the outcome remains poor.</p><p><strong>Objectives: </strong>To assess pharmacokinetic (PK) and pharmacodynamic (PD) data of antiviral drugs in the central nervous system (CNS) to optimize the treatment of Herpesviridae encephalitis.</p><p><strong>Sources: </strong>PUBMED search 1950 to September 2024, terms (1) \"encephalitis\" and (\"HSV\" or \"VZV\" or \"CMV\") or (2) cerebrospinal and (\"(val)acyclovir\" or \"(val)ganciclovir\" or \"foscarnet\" or \"cidofovir\").</p><p><strong>Content: </strong>Antivirals against herpes viruses apparently act in a time-dependent manner. To suppress viral replication, drug concentration in the extracellular space at the site of the infection should be kept above the concentrations active in cell cultures for 24 h/d. Most data reflect delayed drug entry into lumbar cerebrospinal fluid (CSF). Ratios of the areas of the concentration/time curves (AUC) in CSF and serum (AUC<sub>CSF</sub>/AUC<sub>S</sub>) of acyclovir, ganciclovir and foscarnet are 0.15-0.3 in the absence of meningeal inflammation and increase in severe meningoencephalitis. Elimination half-lives (t<sub>1/2β</sub>) are longer in CSF than in plasma. CSF concentrations are rough approximations of drug concentrations in the cerebral extracellular fluid. Lumbar CSF concentrations are usually higher than ventricular or cisternal CSF concentrations tending to overestimate cerebral extracellular fluid concentrations. Provided the availability of adequate measurements in individual CNS compartments, antiviral concentrations and efficacy may be predicted by future PK/PD modelling. Probenecid holds the potential to reduce the efflux of antiviral drugs from the CNS.</p><p><strong>Implications: </strong>The long t<sub>1/2β</sub> of antiviral drugs in CSF suggest relatively uniform steady state CSF levels at dosing intervals ≤12h and accumulation after repeated dosing. Probenecid is of unproven utility. To rapidly attain effective concentrations in the infected tissue, physiologically based pharmacokinetic and PK/PD modelling may be helpful. Until reliable PK/PD data are available, doubling the first dose should be considered.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al. 关于Poirel 等人撰写的 "舒巴坦-杜鲁巴坦对产生 NDM 的大肠埃希菌(包括头孢克肟和阿曲南唑内酰胺耐药分离株)的体外活性"。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-12 DOI: 10.1016/j.cmi.2024.12.010
Balaji Veeraraghavan, Kamini Walia, Adrian Egli
{"title":"Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al.","authors":"Balaji Veeraraghavan, Kamini Walia, Adrian Egli","doi":"10.1016/j.cmi.2024.12.010","DOIUrl":"10.1016/j.cmi.2024.12.010","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers in paediatric bacterial meningitis: a systematic review and meta-analysis of diagnostic test accuracy. 儿科细菌性脑膜炎的生物标志物:诊断测试准确性的系统回顾和荟萃分析。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-12 DOI: 10.1016/j.cmi.2024.12.009
Nina S Groeneveld, Merijn W Bijlsma, Diederik van de Beek, Matthijs C Brouwer

Background: Biomarkers for paediatric bacterial meningitis are essential for an accurate diagnosis.

Objectives: To perform a systematic review of diagnostic accuracy on cerebrospinal fluid (CSF) and blood biomarkers for paediatric bacterial meningitis.

Data sources: Databases Medline, Excerpta Medica Database, Scopus, and Web of Science were used.

Study eligibility criteria: Eligible studies were those on novel diagnostic CSF and blood biomarkers from which data on biomarker concentration or diagnostic accuracy could be abstracted.

Participants: Paediatric patients (0-18 years) suspected of a central nervous system (CNS) infection.

Assessment of risk of bias: The Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS)-2 tool was used to assess risk of bias.

Methods of data synthesis: The difference in biomarker concentrations were assessed by calculating standardized and weighted mean differences. A random-effects meta-analysis model was used. Hierarchical summary receiver-operating characteristic curves were constructed.

Results: We identified 3435 studies, of which 112 articles on 113 individual biomarkers (CSF n = 90 and blood n = 23) were included. In CSF, C-reactive protein (CRP), Interleukin (IL)-6, Tumor necrosis factor (TNF)-α, and Interleukin (IL)-8 showed the largest mean differences between bacterial meningitis and viral meningitis and IL-6, TNF-α, and IL-8 between bacterial meningitis and no CNS infection/inflammation. CSF CRP and ferritin showed excellent discrimination for bacterial versus viral meningitis (summary area under the curve [sAUC] 0.94; 95% CI, 0.92-0.97, sAUC 0.94; 95% CI, 0.90-1.0). CSF IL-6 and procalcitonin showed excellent discrimination for bacterial versus nonbacterial meningitis and versus no CNS infection/inflammation (sAUC IL-6: 0.98; 95% CI, 0.96-1.00, sAUC procalcitonin: 0.96; 95% CI, 0.94-0.99). Procalcitonin in blood showed good discrimination (AUC, 0.89; 95% CI, 0.68-1.00).

Discussion: We identified several CSF biomarkers with high diagnostic accuracy for the diagnosis of bacterial meningitis, including IL-6, procalcitonin, CRP, and ferritin. None of the blood biomarkers exhibited excellent discrimination for paediatric bacterial meningitis. Validation of these biomarkers in prospective, well-designed studies of diagnostic accuracy performed in children with suspected meningitis is needed.

背景:儿童细菌性脑膜炎的生物标志物对准确诊断至关重要:儿科细菌性脑膜炎的生物标志物对于准确诊断至关重要:对儿科细菌性脑膜炎的脑脊液(CSF)和血液生物标志物的诊断准确性进行系统回顾:数据来源:使用 Medline、Excerpta Medica Database、Scopus 和 Web of Science 等数据库:符合条件的研究是关于新型诊断性脑脊液和血液生物标记物的研究,这些研究中的生物标记物浓度或诊断准确性数据可以被摘录:疑似中枢神经系统(CNS)感染的儿童患者(0-18 岁):采用QUADAS-2工具评估偏倚风险:通过计算标准化和加权平均差来评估生物标志物浓度的差异。采用随机效应荟萃分析模型。构建了分层汇总接收者-操作特征曲线:我们确定了 3,435 项研究,其中 112 篇文章涉及 113 个生物标记物(CSF n=90,血液 n=23)。在 CSF 中,CRP、IL-6、TNF-α 和 IL-8 在细菌性脑膜炎和病毒性脑膜炎之间的平均差异最大,而 IL-6、TNF-α 和 IL-8 在细菌性脑膜炎和无中枢神经系统感染/炎症之间的平均差异最大。CSF CRP 和铁蛋白对细菌性脑膜炎和病毒性脑膜炎有很好的鉴别作用(曲线下面积 [sAUC] 0.94,95% CI 0.92-0.97;sAUC 0.94,95% CI 0.90-1.0)。CSF中的IL-6和降钙素原对细菌性与非细菌性脑膜炎以及无中枢神经系统感染/炎症有很好的鉴别作用(sAUC IL-6:0.98;95% CI 0.96-1.00;sAUC 降钙素原:0.96;95% CI 0.94-0.99)。血液中的降钙素显示出良好的分辨能力(AUC 0.89; 95% CI 0.68-1.00):我们发现了几种诊断细菌性脑膜炎准确率较高的脑脊液生物标志物,包括IL-6、降钙素原、CRP和铁蛋白。没有一种血液生物标记物对儿科细菌性脑膜炎有很好的鉴别力。需要在对疑似脑膜炎患儿进行的前瞻性设计良好的诊断准确性研究中对这些生物标志物进行验证:crd42022361785.
{"title":"Biomarkers in paediatric bacterial meningitis: a systematic review and meta-analysis of diagnostic test accuracy.","authors":"Nina S Groeneveld, Merijn W Bijlsma, Diederik van de Beek, Matthijs C Brouwer","doi":"10.1016/j.cmi.2024.12.009","DOIUrl":"10.1016/j.cmi.2024.12.009","url":null,"abstract":"<p><strong>Background: </strong>Biomarkers for paediatric bacterial meningitis are essential for an accurate diagnosis.</p><p><strong>Objectives: </strong>To perform a systematic review of diagnostic accuracy on cerebrospinal fluid (CSF) and blood biomarkers for paediatric bacterial meningitis.</p><p><strong>Data sources: </strong>Databases Medline, Excerpta Medica Database, Scopus, and Web of Science were used.</p><p><strong>Study eligibility criteria: </strong>Eligible studies were those on novel diagnostic CSF and blood biomarkers from which data on biomarker concentration or diagnostic accuracy could be abstracted.</p><p><strong>Participants: </strong>Paediatric patients (0-18 years) suspected of a central nervous system (CNS) infection.</p><p><strong>Assessment of risk of bias: </strong>The Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS)-2 tool was used to assess risk of bias.</p><p><strong>Methods of data synthesis: </strong>The difference in biomarker concentrations were assessed by calculating standardized and weighted mean differences. A random-effects meta-analysis model was used. Hierarchical summary receiver-operating characteristic curves were constructed.</p><p><strong>Results: </strong>We identified 3435 studies, of which 112 articles on 113 individual biomarkers (CSF n = 90 and blood n = 23) were included. In CSF, C-reactive protein (CRP), Interleukin (IL)-6, Tumor necrosis factor (TNF)-α, and Interleukin (IL)-8 showed the largest mean differences between bacterial meningitis and viral meningitis and IL-6, TNF-α, and IL-8 between bacterial meningitis and no CNS infection/inflammation. CSF CRP and ferritin showed excellent discrimination for bacterial versus viral meningitis (summary area under the curve [sAUC] 0.94; 95% CI, 0.92-0.97, sAUC 0.94; 95% CI, 0.90-1.0). CSF IL-6 and procalcitonin showed excellent discrimination for bacterial versus nonbacterial meningitis and versus no CNS infection/inflammation (sAUC IL-6: 0.98; 95% CI, 0.96-1.00, sAUC procalcitonin: 0.96; 95% CI, 0.94-0.99). Procalcitonin in blood showed good discrimination (AUC, 0.89; 95% CI, 0.68-1.00).</p><p><strong>Discussion: </strong>We identified several CSF biomarkers with high diagnostic accuracy for the diagnosis of bacterial meningitis, including IL-6, procalcitonin, CRP, and ferritin. None of the blood biomarkers exhibited excellent discrimination for paediatric bacterial meningitis. Validation of these biomarkers in prospective, well-designed studies of diagnostic accuracy performed in children with suspected meningitis is needed.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting diagnostics: multiplex PCR system for rapid diagnosis of respiratory virus infections: can we do better? 重新审视诊断:用于快速诊断呼吸道病毒感染的多重 PCR 系统:我们能做得更好吗?
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-12 DOI: 10.1016/j.cmi.2024.12.006
Slim Fourati, Paul Loubet
{"title":"Revisiting diagnostics: multiplex PCR system for rapid diagnosis of respiratory virus infections: can we do better?","authors":"Slim Fourati, Paul Loubet","doi":"10.1016/j.cmi.2024.12.006","DOIUrl":"10.1016/j.cmi.2024.12.006","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scope and aims of European society of clinical microbiology and infectious diseases guidelines: a white paper. ESCMID 指南的范围和目标:白皮书。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-11 DOI: 10.1016/j.cmi.2024.11.033
Luigia Scudeller, Effrossyni Gkrania-Klotsas, José Ramon Pano Pardo
{"title":"Scope and aims of European society of clinical microbiology and infectious diseases guidelines: a white paper.","authors":"Luigia Scudeller, Effrossyni Gkrania-Klotsas, José Ramon Pano Pardo","doi":"10.1016/j.cmi.2024.11.033","DOIUrl":"10.1016/j.cmi.2024.11.033","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of molecular tests for diagnosis of bloodstream infections in the clinical setting: a systematic literature review and meta-analysis. 临床环境中用于诊断血流感染的分子检验的性能:系统性文献综述和荟萃分析。
IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-12-11 DOI: 10.1016/j.cmi.2024.12.007
Yu Wang, Kristina Lindsley, Tammy C Bleak, Sarah Jiudice, Jennifer Uyei, Yifan Gu, Yi Wang, Tristan T Timbrook, Joan-Miquel Balada-Llasat

Background: Rapid identification of bloodstream pathogens and associated antimicrobial resistance (AMR) profiles by molecular tests from positive blood cultures (PBCs) have the potential to improve patient management and clinical outcomes.

Objectives: A systematic review and meta-analysis were conducted to evaluate diagnostic test accuracy (DTA) of molecular tests from PBCs for detecting pathogens and AMR in the clinical setting.

Methods: .

Data sources: Medline, Embase, Cochrane, conference proceedings, and study bibliographies were searched.

Study eligibility criteria: Studies evaluating DTA of commercially available molecular tests vs. traditional phenotypic identification and susceptibility testing methods in patients with PBCs were eligible.

Participants: Patients with PBCs.

Tests: Commercially available molecular tests.

Reference standard: Traditional phenotypic identification and susceptibility testing methods (standard of care, SOC).

Assessment of risk of bias: Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2.

Methods of data synthesis: Summary DTA outcomes were estimated using bivariate random-effects models for gram-negative bacteria (GNB), gram-positive bacteria (GPB), yeast, GNB-AMR, GPB-AMR, and specific targets when reported by ≥ 2 studies (PROSPERO CRD42023488057).

Results: Seventy-four studies including 24 590 samples were analysed, most of which had a low risk of bias. When compared with SOC, molecular tests showed 92-99% sensitivity, 99-100% specificity, 99-100% positive predictive value, and 97-100% negative predictive value for identifying total GNB (43 studies), GPB (38 studies), yeast (24 studies), GNB-AMR (35 studies), and GPB-AMR (39 studies). For individual pathogen targets, 93-100% sensitivity, 98-100% specificity, 86-100% positive predictive value, and 99-100% negative predictive value were estimated. Five of seven AMR genes had 91-99% sensitivity and 99-100% specificity. Sensitivity was lower for IMP (four studies; 62%; 95% CI, 34-83%) and VIM (four studies; 70%; 95% CI, 38-90%) carbapenemases, where genes were not detected or were not harboured in Pseudomonas aeruginosa (i.e. low prevalence). Performance of molecular tests in detecting AMR was generally comparable when grouped by geographical region (Europe, North America, and East Asia).

Discussion: High DTA support the use of molecular tests in identifying a broad panel of pathogens and detecting AMR in GNB and GPB.

背景:通过分子检验从阳性血培养物(PBCs)中快速鉴定血流病原体和相关抗菌素耐药性(AMR)概况有可能改善患者管理和临床结果:进行了一项系统综述和荟萃分析,以评估临床环境中通过 PBC 分子检验检测病原体和 AMR 的诊断检测准确性 (DTA):研究资格标准:研究资格标准:评估商用分子检验的 DTA 与 PBC 患者的传统表型鉴定和药敏试验方法 (SOC) 的研究:方法:使用 QUADAS-2 评估研究质量。使用双变量随机效应模型对革兰阴性菌(GNB)、革兰阳性菌(GPB)、酵母菌、GNB-AMR、GPB-AMR 和特定靶标的 DTA 结果摘要进行估算(PROSPERO CRD42023488057):分析了包括 24,590 个样本在内的 74 项研究,其中大多数研究的偏倚风险较低。与 SOC 相比,分子检测在识别总 GNB(43 项研究)、GPB(38 项研究)、酵母菌(24 项研究)、GNB-AMR(35 项研究)和 GPB-AMR (39 项研究)方面的灵敏度为 92-99%,特异性为 99-100%,阳性预测值为 99-100%,阴性预测值为 97-100%。对于单个病原体目标,估计灵敏度为 93-100%,特异性为 98-100%,PPV 为 86-100%,NPV 为 99-100%。7 个 AMR 基因中有 5 个的灵敏度为 91-99%,特异性为 99-100%。IMP(4 项研究;62%,95%CI 34%-83%)和 VIM(4 项研究;70%,95%CI 38%-90%)碳青霉烯酶的灵敏度较低,这些基因在铜绿假单胞菌中未被检测到或不存在(即流行率低)。按地理区域(欧洲、北美和东亚)分组后,分子检测在检测 AMR 方面的性能基本相当:高 DTA 支持在 GNB 和 GPB 中使用分子检验来鉴定各种病原体和检测 AMR。
{"title":"Performance of molecular tests for diagnosis of bloodstream infections in the clinical setting: a systematic literature review and meta-analysis.","authors":"Yu Wang, Kristina Lindsley, Tammy C Bleak, Sarah Jiudice, Jennifer Uyei, Yifan Gu, Yi Wang, Tristan T Timbrook, Joan-Miquel Balada-Llasat","doi":"10.1016/j.cmi.2024.12.007","DOIUrl":"10.1016/j.cmi.2024.12.007","url":null,"abstract":"<p><strong>Background: </strong>Rapid identification of bloodstream pathogens and associated antimicrobial resistance (AMR) profiles by molecular tests from positive blood cultures (PBCs) have the potential to improve patient management and clinical outcomes.</p><p><strong>Objectives: </strong>A systematic review and meta-analysis were conducted to evaluate diagnostic test accuracy (DTA) of molecular tests from PBCs for detecting pathogens and AMR in the clinical setting.</p><p><strong>Methods: </strong>.</p><p><strong>Data sources: </strong>Medline, Embase, Cochrane, conference proceedings, and study bibliographies were searched.</p><p><strong>Study eligibility criteria: </strong>Studies evaluating DTA of commercially available molecular tests vs. traditional phenotypic identification and susceptibility testing methods in patients with PBCs were eligible.</p><p><strong>Participants: </strong>Patients with PBCs.</p><p><strong>Tests: </strong>Commercially available molecular tests.</p><p><strong>Reference standard: </strong>Traditional phenotypic identification and susceptibility testing methods (standard of care, SOC).</p><p><strong>Assessment of risk of bias: </strong>Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2.</p><p><strong>Methods of data synthesis: </strong>Summary DTA outcomes were estimated using bivariate random-effects models for gram-negative bacteria (GNB), gram-positive bacteria (GPB), yeast, GNB-AMR, GPB-AMR, and specific targets when reported by ≥ 2 studies (PROSPERO CRD42023488057).</p><p><strong>Results: </strong>Seventy-four studies including 24 590 samples were analysed, most of which had a low risk of bias. When compared with SOC, molecular tests showed 92-99% sensitivity, 99-100% specificity, 99-100% positive predictive value, and 97-100% negative predictive value for identifying total GNB (43 studies), GPB (38 studies), yeast (24 studies), GNB-AMR (35 studies), and GPB-AMR (39 studies). For individual pathogen targets, 93-100% sensitivity, 98-100% specificity, 86-100% positive predictive value, and 99-100% negative predictive value were estimated. Five of seven AMR genes had 91-99% sensitivity and 99-100% specificity. Sensitivity was lower for IMP (four studies; 62%; 95% CI, 34-83%) and VIM (four studies; 70%; 95% CI, 38-90%) carbapenemases, where genes were not detected or were not harboured in Pseudomonas aeruginosa (i.e. low prevalence). Performance of molecular tests in detecting AMR was generally comparable when grouped by geographical region (Europe, North America, and East Asia).</p><p><strong>Discussion: </strong>High DTA support the use of molecular tests in identifying a broad panel of pathogens and detecting AMR in GNB and GPB.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Microbiology and Infection
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1